Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.

Shannon S, Jia D, Entersz I, Beelen P, Yu M, Carcione C, Carcione J, Mahtabfar A, Vaca C, Weaver M, Shreiber D, Zahn JD, Liu L, Lin H, Foty RA.

BMC Cancer. 2017 Feb 10;17(1):121. doi: 10.1186/s12885-017-3107-x.

2.

Transcriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data.

De Wolf H, De Bondt A, Turner H, Göhlmann HW.

Assay Drug Dev Technol. 2016 May;14(4):252-60. doi: 10.1089/adt.2016.715.

PMID:
27187605
3.

A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction.

Haider S, Rahman R, Ghosh S, Pal R.

PLoS One. 2015 Dec 10;10(12):e0144490. doi: 10.1371/journal.pone.0144490. eCollection 2015.

4.
5.

MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF.

Wang Z, Ma B, Ji X, Deng Y, Zhang T, Zhang X, Gao H, Sun H, Wu H, Chen X, Zhao R.

Cancer Cell Int. 2015 Apr 15;15:40. doi: 10.1186/s12935-015-0192-2. eCollection 2015.

6.

PTEN: Multiple Functions in Human Malignant Tumors.

Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L.

Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Review.

7.

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.

Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, Porru M, Leonetti C, Di Carlo S, Visca P, Brizzi MF, Anichini A, Mortarini R, Falcioni R.

Oncotarget. 2015 Feb 20;6(5):2779-93.

8.

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.

Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.

BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.

9.

DA-Raf-dependent inhibition of the Ras-ERK signaling pathway in type 2 alveolar epithelial cells controls alveolar formation.

Watanabe-Takano H, Takano K, Sakamoto A, Matsumoto K, Tokuhisa T, Endo T, Hatano M.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2291-300. doi: 10.1073/pnas.1321574111. Epub 2014 May 19.

10.

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, Hung KE.

Cancer Lett. 2014 Jun 1;347(2):204-11. doi: 10.1016/j.canlet.2014.02.018. Epub 2014 Feb 24.

11.

Systemic therapy of non-resectable metastatic melanoma.

Orouji A, Goerdt S, Utikal J.

Cancers (Basel). 2010 May 26;2(2):955-69. doi: 10.3390/cancers2020955.

12.

Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.

Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, Biffoni M, Pagliuca A, Martinetti D, Memeo L, Milella M, De Maria R, Eramo A.

J Exp Clin Cancer Res. 2013 Nov 16;32:91. doi: 10.1186/1756-9966-32-91.

13.

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S.

Clin Cancer Res. 2013 Nov 15;19(22):6219-29. doi: 10.1158/1078-0432.CCR-13-0145. Epub 2013 Sep 17.

14.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Beloueche-Babari M, Jamin Y, Arunan V, Walker-Samuel S, Revill M, Smith PD, Halliday J, Waterton JC, Barjat H, Workman P, Leach MO, Robinson SP.

Br J Cancer. 2013 Sep 17;109(6):1562-9. doi: 10.1038/bjc.2013.456. Epub 2013 Aug 13.

15.

Typical cell signaling response to ionizing radiation: DNA damage and extranuclear damage.

Yu H.

Chin J Cancer Res. 2012 Jun;24(2):83-9. doi: 10.1007/s11670-012-0083-1.

16.

Current and future trials of targeted therapies in cutaneous melanoma.

Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ.

Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Review.

17.

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.

J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10.

18.

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM.

Mol Cancer. 2012 Oct 5;11:75. doi: 10.1186/1476-4598-11-75.

19.

p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ, Klein-Szanto AJ, Gutkind JS, Hoeflich KP, Chernoff J.

Cancer Res. 2012 Nov 15;72(22):5966-75. doi: 10.1158/0008-5472.CAN-12-2246. Epub 2012 Sep 14.

20.

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J.

Mol Cancer Ther. 2012 May;11(5):1193-202. doi: 10.1158/1535-7163.MCT-12-0098. Epub 2012 Mar 12.

Supplemental Content

Support Center